Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
15 2월 2024 - 6:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G/A
Under
the Securities Exchange Act of 1934
(Amendment
No. 2)*
Landos
Biopharma, Inc.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
515069102
(CUSIP
Number)
December
31, 2023
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☐
Rule 13d-1(c)
☒
Rule 13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a
prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 515069102 |
13G/A |
Page
2 of 5 Pages |
1. |
NAMES
OF REPORTING PERSONS
Josep
Bassaganya-Riera |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see
instructions)
(a)
☐
(b)
☐ |
3. |
SEC
USE ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
|
5. |
|
SOLE
VOTING POWER
0
|
|
6. |
|
SHARED
VOTING POWER
0 |
|
7. |
|
SOLE
DISPOSITIVE POWER
0 |
|
8. |
|
SHARED
DISPOSITIVE POWER
0 |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see
instructions) ☐
|
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% |
12. |
TYPE
OF REPORTING PERSON (see instructions)
IN |
CUSIP
No. 515069102 |
13G/A |
Page
3 of 5 Pages |
Item
1.
|
(a) |
Name
of Issuer |
|
|
|
|
|
Landos
Biopharma, Inc. |
|
|
|
|
(b) |
Address
of Issuer’s Principal Executive Offices |
|
|
|
|
|
P.O.
Box 11239, Blacksburg VA 24062 |
Item
2.
|
(a) |
Name
of Person Filing |
|
|
|
|
|
Josep
Bassaganya-Riera |
|
|
|
|
(b) |
Address
of the Principal Office or, if none, residence |
|
|
|
|
|
1013 Mcbryde Lane, Blacksburg VA 24060 |
|
|
|
|
(c) |
Citizenship |
|
|
|
|
|
USA |
|
|
|
|
(d) |
Title
of Class of Securities |
|
|
|
|
|
Common
Stock |
|
|
|
|
(e) |
CUSIP
Number |
|
|
|
|
|
515069102 |
Item
3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
N/A
Item
4. Ownership.
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
(a) |
Amount
beneficially owned: 0 |
|
|
|
|
|
(b) |
Percent
of class: 0% |
|
|
|
|
|
(c) |
Number
of shares as to which the person has: |
|
|
|
|
|
|
(i) |
Sole
power to vote or to direct the vote 0 |
|
|
|
|
|
|
(ii) |
Shared
power to vote or to direct the vote 0 |
|
|
|
|
|
|
(iii) |
Sole
power to dispose or to direct the disposition of 0 |
|
|
|
|
|
|
(iv) |
Shared
power to dispose or to direct the disposition of 0 |
CUSIP
No. 515069102 |
13G/A |
Page
4 of 5 Pages |
Item
5. Ownership of Five Percent or Less of a Class.
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than 5 percent of the class of securities, check the following [X].
Item
6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
or Control Person.
N/A
Item
8. Identification and Classification of Members of the Group.
N/A
Item
9. Notice of Dissolution of Group.
N/A
Item
10. Certification.
N/A
CUSIP
No. 515069102 |
13G/A |
Page
5 of 5 Pages |
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
|
02/14/2024 |
|
Date |
|
|
|
/s/
Josep Bassaganya-Riera |
|
Signature |
|
|
|
Josep
Bassaganya-Riera |
|
Name/Title |
Landos Biopharma (NASDAQ:LABP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Landos Biopharma (NASDAQ:LABP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024